

ملاحظات:



Hepatic Manifestations of Pediatric Hemophagocytic Lymphohistocytosis

Thesis

*Submitted for Partial Fulfillment of Master
Degree in Pediatrics*

By

Fatma Mohamed Azazy Elshorbagy

M.B, B.Ch.: Faculty of Medicine Ain Shams University; 2017

Under Supervision of

Prof. Manal Hamdy El-Sayed

Professor of Pediatrics

Faculty of Medicine, Ain Shams University

Prof. Iman Ahmed Ragab

Professor of Pediatrics

Faculty of Medicine, Ain Shams University

Prof. Fatma Soliman Ebeid

Professor of Pediatrics

Faculty of Medicine, Ain Shams University

Dr. Salwa Mostafa Abd El Kader

Lecturer of Pediatrics

Faculty of Medicine, Ain Shams University

*Faculty of Medicine
Ain Shams University*

2022

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

لَسْبَدَانِكَ لَا نَعْلَمُ لَنَا
إِلَّا مَا عَلَّمْتَنَا إِنَّكَ أَنْتَ
الْعَلِيمُ الْعَظِيمُ

صدق الله العظيم

سورة البقرة الآية: ٣٢

Acknowledgments

*First and foremost, I feel always indebted to **Allah** the Most Beneficent and Merciful.*

I wish to express my deepest thanks, gratitude and appreciation to Prof. Manal Hamdy El-Sayed, Professor of Pediatrics, Faculty of Medicine, Ain Shams University, for her meticulous supervision, kind guidance, valuable instructions and generous help.

Special thanks are due to Prof. Iman Ahmed Ragab, Professor of Pediatrics, Faculty of Medicine, Ain Shams University, for her sincere efforts, fruitful encouragement.

I am deeply thankful to Prof. Fatma Soliman Ebeid, Professor of Pediatrics, Faculty of Medicine, Ain Shams University, for her great help, outstanding support, active participation and guidance.

Last but not least my sincere thanks and appreciation to Dr. Salwa Mostafa Abd El Kader, Lecturer of Pediatrics, Faculty of Medicine, Ain Shams University, for her supervision, continuous help, encouragement throughout this work and tremendous effort.

I would like to express my hearty thanks to all my family for their support till this work was completed.

Fatma Mohamed Azazy Elshorbagy

List of Contents

| Title | Page No. |
|---|----------|
| List of Tables..... | i |
| List of Figures | iii |
| List of Abbreviations | v |
| Abstract..... | vi |
| Introduction | 1 |
| Aim of the Work..... | 3 |
| Review of Literature | |
| Chapter 1: Hemophagocytic Lymphohistiocytosis | 4 |
| Chapter 2: Genetic Causes of HLH | 17 |
| Chapter 3: Hepatic Involvement in HLH | 36 |
| Patients and Methods..... | 43 |
| Results..... | 49 |
| Discussion | 80 |
| Summary and Conclusion | 89 |
| Recommendations..... | 93 |
| References | 94 |
| Arabic Summary | |

List of Tables

| Table No. | Title | Page No. |
|------------------|--|----------|
| Table 1: | Classification of hemophagocytic lymphohistiocytosis | 7 |
| Table 2: | Parameters Included in the Adapted HLH-2004 Guidelines and H-Score and the Number of Points Associated With Each Criterion for Scoring | 10 |
| Table 3: | Diagnostic criteria for HLH | 12 |
| Table 4: | Primary HLH subtypes and related genetic mutation..... | 19 |
| Table 5: | Diagnostic criteria for HLH | 44 |
| Table 6: | The French investigators proposed to adopt a new objective scoring system (HLH probability score or H Score) | 45 |
| Table 7: | Demographic data of the studied patients with HLH..... | 49 |
| Table 8: | Classification of patients with HLH according to their genotype | 50 |
| Table 9: | Descriptive data of the clinical presentation of patients with HLH..... | 52 |
| Table 10: | Hepatic presentation (Radiological and pathological) of the studied patients with HLH..... | 53 |
| Table 11: | Reactivation characters of the studied patients with HLH. | 54 |
| Table 12: | Outcome of studied patients with HLH..... | 55 |
| Table 13: | Comparison of demographic data of patients with HLH according to hepatic involvement..... | 58 |
| Table 14: | Comparison of type of HLH and type of mutant gene of patients with HLH according to hepatic involvement..... | 59 |

List of Tables cont...

| Table No. | Title | Page No. |
|------------------|--|----------|
| Table 15: | Comparison of clinical presentation and the size of the liver and spleen of patients with HLH according to hepatic involvement | 60 |
| Table 16: | Comparison of CMV and EBV affection of patients with HLH according to hepatic involvement..... | 61 |
| Table 17: | Comparison of radiological and pathological results of patients with HLH according to hepatic involvement | 63 |
| Table 18: | Comparison of outcome and HSCT Of patients with HLH according to hepatic involvement..... | 64 |
| Table 19: | Overall survival between the two groups | 65 |
| Table 20: | Comparison of laboratory results of patients with HLH according to hepatic involvement..... | 66 |
| Table 21: | Comparison of initial laboratory results at presentation and during HLH reactivation..... | 75 |
| Table 22: | Comparison of laboratory results of patients with HLH | 77 |

List of Figures

| Fig. No. | Title | Page No. |
|-------------------|--|----------|
| Figure 1: | Pathophysiology of HLH | 8 |
| Figure 2: | Overview of the current diagnostic approach to FHL | 18 |
| Figure 3: | Mechanism of HLH..... | 35 |
| Figure 4: | Cytokine basis of HLH associated hepatic dysfunction..... | 37 |
| Figure 5: | Classification of patients with HLH according to their genotype..... | 51 |
| Figure 6: | Duration till reactivation (months) in total group. | 56 |
| Figure 7: | Kaplan meier survival curve for overall survival of patients with HLH. | 57 |
| Figure 8: | Comparison of CMV and EBV affection of patients with HLH according to hepatic involvement..... | 62 |
| Figure 9: | Comparison between no liver involvement and liver involvement according to INR | 72 |
| Figure 10: | Kaplan meier survival curve for reactivation free survival of patients with HLH according to hepatic biochemical involvement..... | 73 |
| Figure 11: | Survival curve in hepatic involvement versus OS, reactivation free survival. | 74 |
| Figure 12: | Progress of hemoglobin level (gm/dl) in patients with HLH in the initial presentation, week 2, week 8, end of treatment and in reactivation. | 78 |

List of Figures cont...

| Fig. No. | Title | Page No. |
|-------------------|---|----------|
| Figure 13: | Box and Plot chart showing progress of WBCs in patients with HLH in the initial presentation, week 2, week 8, end of the treatment and in reactivation..... | 78 |
| Figure 14: | Box and plot chart showing progress of platelets in patient with HLH in the initial presentation, week 2, week 8, end of the treatment and in the reactivation..... | 79 |

List of Abbreviations

| Abb. | Full term |
|------------|---|
| BIR2 | Baculovirus IAP repeat |
| CBC | Complete blood counts |
| CNS | Central nervous system |
| CTL | Cytotoxic T lymphocyte |
| DIC | Disseminated intravascular coagulation |
| EBV | Epstein-Barr virus |
| EBV | Epstein-Barr virus |
| FH..... | Family history |
| FHL2 | Familial hemophagocytic lymphohistiocytosis type 2 |
| GS2..... | Griscelli syndrome type 2 |
| HCT | Hematopoietic cell transplantation |
| HLH | Emophagocytic lymphohistiocytosis |
| HPS2 | Hermansky-Pudlak type 2 |
| ICUs | Intensive care units |
| IQR..... | Interquartile range |
| LDH | Lactate dehydrogenase |
| MOD | Multi organ dysfunction |
| MRI | Magnetic resonance imaging |
| NK | Natural killer |
| NOD | Nucleotide-binding oligomerization domain containing |
| PID | Primary immune deficiency |
| PT | Prothrombin time |
| PTT | Partial thromboplastin time |
| SD | Standard deviation |
| SLAM | Signaling lymphocyte activation molecule |
| UCBT | Unrelated donor cord blood transplantation |
| XIAP | Xlinked inhibitor of apoptosis protein |
| XLP-1..... | X-linked lymphoproliferative disease 1 |
| XLP-2..... | X-linked lymphoproliferative syndrome type 2 |

ABSTRACT

Background: Hemophagocytic lymphohistiocytosis (HLH) is a rare hyper-inflammatory disorder caused by benign systemic overgrowth of macrophages in the reticulo-endothelial system leading to cytokine storm. The main features of HLH are; fever, splenomegaly, bi/pancytopenia; hyper-ferritinemia, hyper-triglyceridemia and hypofibrinogenemia; which if not diagnosed and early treated progresses to disseminated intravascular coagulation (DIC), multi-organ dysfunction with dismal outcome. Hepatic manifestations are not well recognized primary presentation in pediatric patients with HLH. This presentation mandates high levels of suspicion for early diagnosis.

Aim of the Work: To study the hepatic involvement clinical, laboratory, and pathological in patients clinically diagnosed or genetically confirmed Familial/primary (1ry) HLH and in patients with secondary (2ry) acquired HLH.

Patients and Methods: A 6 month retrospective cohort study included 35 patients with genetically confirmed HLH divided into familial HLH by its types, X linked lymphoproliferative syndrome and HLH with partial albinism; following at pediatric hematology/oncology clinic, Ain Shams University. In the studied patients, detailed review of patient's clinical, laboratory data of HLH, hepatic transaminases and synthetic liver functions were done at time of presentation, at week 2, 8 from treatment start and at time of reactivation; Liver biopsy results and genetic analysis were recorded. Biochemical liver involvement was considered when alanine aminotransferase was 3 more the upper level of normal at presentation. Overall and reactivation free survival were analyzed according to liver involvement.

Results: Thirty five patients with HLH were recruited with age range of 2-108 months, 62.9% of patients with HLH were genetically confirmed and 34.3% of them had MUNC13D mutations, 8.6% had STXBP2 mutation and 14.3% had RAB27A mutation while 11.4% had secondary HLH.; 82.9%) had liver enlargement at diagnosis with hepatic reactivation in 51.4%. 22.8% of patients had biochemical liver involvement; there was no significant difference in their demographic data or their clinical presentation, their final outcome or the type of mutant gene according to liver involvement.

Conclusion: Variable transaminitis and synthetic liver dysfunction might be the presenting manifestation of HLH and upon reactivation. Significant biochemical liver involvement is an under recognized presentation of HLH. Hepatic involvement did not impact response to treatment and disease outcome.

Keywords: Hemophagocytic Lymphohistiocytosis, Disseminated Intravascular Coagulation.

INTRODUCTION

Hemophagocytic lymphohistiocytosis (HLH); is a potentially catastrophic rare hyperinflammatory syndrome occurring due to hyperactive immune system responses (*Rosado and Kim, 2013*). First cases were described as “histiocytic medullary reticulocytosis” by Scott Robin and Smith in 1939, following which several changes in the disease nomenclature took place (*Hayden et al., 2016*).

Classically, HLH has been divided into two types: (i) primary HLH which is attributed to germline mutations implicated in the cytotoxic dysfunction of the NK cell/CTL presenting mainly in infancy and early childhood; and (ii) acquired HLH which occurs in elder population (*Janka and Lehmborg, 2016*).

The clinical findings of pediatric HLH are usually non-specific. The important criteria to diagnose initially as HLH that was proposed by the HLH-2004 study include persistent fever that is resistant to antibiotics and splenomegaly with or without hepatomegaly (*Henter et al., 2007*).

Since 2004 HLH diagnostic criteria, diagnosis of pediatric HLH incorporated the mutational/genetic analysis as a “major criterion” for primary HLH diagnosis (*Hayden et al., 2016*).

While HLH Hepatobiliary disorder is being increasingly described in both pediatric and adults; the characteristics of

hepatic affection still yet poorly understood (*Ost et al., 1998*). Organomegaly with elevated liver enzymes, biphasic hyperbilirubinemia and coagulopathy can occur early in the disease, presenting a challenging diagnosis of hepatobiliary HLH (*Fardet et al., 2014*).

In rare instances acute hepatic failure may dominate the clinical picture, which in combination with hyperferritinemia, may mimic neonatal hemochromatosis (*Chen et al., 2010*).

Cytokine mediated hepatic damage includes wide range of biochemical changes such as hyperferritinemia, hypertriglyceridemia, hypofibrinogenemia, coagulopathy, disseminated intravascular coagulation (DIC) and multi organ dysfunction (MOD); which if not treated early, may lead to death in virtually all the patients (*Rosado and Kim, 2013*).

The histopathology of hepatic biopsies in hepatobiliary HLH is not well established owing to rarity of cases with insufficient biopsy data, delayed diagnosis with dismal outcome, sampling bias (needle biopsy vs. wedge biopsy); and associated triggering factors such as virus associated histological alterations; especially in acquired cases (*Padhi et al., 2019*).

AIM OF THE WORK

- **Primary objective:**

Study the hepatic involvement clinical, laboratory, and pathological in patients clinically diagnosed or genetically confirmed 1ry HLH and in patients with 2ry acquired HLH.

- **Secondary objective:**

- Study the frequency of hepatic affection in relation to genetic subtypes, viral induced HLH or other potential trigger.
- Explore the repetition of hepatic affection in sibs affected by HLH.
- Study the hepatic flares in relation to disease reactivation.
- Study the histologic changes in genetically confirmed HLHL.
- Find the relation of final outcome to the severity of hepatic affection.

HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS

Introduction:

Hemophagocytic lymphohistiocytosis (HLH) or hemophagocytic syndrome is a potentially catastrophic hyper inflammatory syndrome occurring in genetically susceptible individuals which results due to hyperactive, inappropriate, excessive immune system activation (*Rosado et al., 2013*).

That results due to impaired cytotoxic T lymphocyte (CTL)/natural killer (NK) cell activity producing uncontrolled proliferation of benign macrophages in all reticuloendothelial organs such as bone marrow, spleen, liver, and lymph nodes.

Hemophagocytic histiocytosis, unexplained peripheral blood cytopenia (s), cytokine storm, cytokine mediated hepatic injury/ dysfunction producing spectrum of biochemical alteration such as hyperferritinemia, hypertriglyceridemia, hypofibrinogenemia, coagulopathy, disseminated intravascular coagulation (DIC), multi organ dysfunction (MOD); and if not diagnosed and treated early, may lead to death in virtually all case (*Janka et al., 2012*).

Since the first description of cases coined as “histiocytic medullary reticulocytosis” by Scott Robin and Smith in 1939, there has been a sequential change in nomenclature of this entity (*Hayden et al., 2016*).